MEDIFAST (MED)
(Delayed Data from NYSE)
$18.44 USD
+0.16 (0.88%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $18.46 +0.02 (0.11%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$18.44 USD
+0.16 (0.88%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $18.46 +0.02 (0.11%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
Zacks News
Medifast (MED) Cuts View Despite Q3 Earnings Beat, Stock Down
by Zacks Equity Research
Medifast's (MED) third-quarter 2022 results reflect reduced Coach productivity and cost inflation. Management curtails guidance.
Medifast's (MED) Q3 Earnings Upcoming: Things Worth Noting
by Zacks Equity Research
Medifast's (MED) third-quarter 2022 results are likely to reflect cost-related challenges, whereas strength in the OPTAVIA lifestyle solution and coaching support system bodes well.
Church & Dwight (CHD) Q3 Earnings Beat Mark, Sales Rise Y/Y
by Zacks Equity Research
Church & Dwight's (CHD) third-quarter 2022 results reflect increased sales on growth in Consumer Domestic and Specialty Products units. However, earnings decline year over year.
Why Is Medifast (MED) Down 19.8% Since Last Earnings Report?
by Zacks Equity Research
Medifast (MED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Medifast (MED) Down More Than 20% in 3 Months on Cost Woes
by Zacks Equity Research
Medifast (MED) has been seeing high SG&A expenses and escalated raw material costs. The company expects short-term margin pressure in 2022 due to inflation and continued investments.
Are Options Traders Betting on a Big Move in Medifast (MED) Stock?
by Zacks Equity Research
Investors need to pay close attention to Medifast (MED) stock based on the movements in the options market lately.
Medifast (MED) Q2 Earnings Top Estimates, Guidance Lowered
by Zacks Equity Research
Medifast's (MED) second-quarter 2022 results reflect increased active earning OPTAVIA Coaches and elevated costs. Management cuts guidance for 2022 due to inflation.
Medifast (MED) Surpasses Q2 Earnings Estimates
by Zacks Equity Research
Medifast (MED) delivered earnings and revenue surprises of 17.99% and 2%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks.com featured highlights include UFP Industries, MEDIFAST, Skyline, Hudson Global and Expeditors International of Washington
by Zacks Equity Research
UFP Industries, MEDIFAST, Skyline, Hudson Global and Expeditors International of Washington are part of Zacks Screen of the Week article.
Medifast (MED) Readies for Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Medifast's (MED) second-quarter 2022 results are likely to reflect gains from its OPTAVIA lifestyle solution and coaching support system, while escalated costs might have been a concern.
Explore DuPont Analysis & Pick 5 Top Stocks
by Sanghamitra Saha
Do you have more faith in DuPont analysis than simple ROE calculation? Tap UFP Industries (UFPI), MEDIFAST (MED), Skyline (SKY), Hudson Global (HSON) and Expeditors International of Washington (EXPD).
Dive Into DuPont Analysis & Pick 5 Top Stocks
by Sanghamitra Saha
Do you have more faith in DuPont analysis than simple ROE calculation? Tap Sanderson Farms (SAFM), MEDIFAST (MED), Skyline (SKY), Hudson Global (HSON) and Expeditors International of Washington (EXPD).
Pilgrim's Pride (PPC) Q2 Earnings Beat, Sales Improve Y/Y
by Zacks Equity Research
Pilgrim's Pride's (PPC) second-quarter 2022 results reflect increased earnings and sales on growth across Mexico and Europe and the U.S. operations.
Hershey (HSY) Beats on Q2 Earnings & Sales, Raises 2022 View
by Zacks Equity Research
Hershey's (HSY) second-quarter 2022 results reflect higher earnings and sales on growth across all segments. Management raises 2022 guidance.
Medifast (MED) is a Top Dividend Stock Right Now: Should You Buy?
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Medifast (MED) have what it takes? Let's find out.
Are Investors Undervaluing Greencore Group (GNCGY) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Kraft Heinz (KHC) Q2 Earnings Top Estimates, Sales Fall Y/Y
by Zacks Equity Research
The Kraft Heinz Company's (KHC) second-quarter 2022 results reflect lower earnings and sales. Nevertheless, management raises the 2022 organic net sales view.
Kimberly-Clark (KMB) Q2 Earnings Miss Mark, Sales Rise Y/Y
by Zacks Equity Research
Kimberly-Clark's (KMB) second-quarter 2022 earnings decline year over year. Nevertheless, sales increase on growth across all segments.
Inter Parfums (IPAR) Ups 2022 Guidance on Robust Q2 Sales
by Zacks Equity Research
Inter Parfums' (IPAR) sales increase year over year in second-quarter 2022. Management raises its top-and bottom-line view for 2022.
Campbell Soup (CPB) Looks Delectable on Solid Brands & Savings
by Zacks Equity Research
Campbell Soup's (CPB) prudent investment and strategic efforts in product innovation and brand building bode well. Also, it is progressing well with cost-saving plans.
Inter Parfums (IPAR) Partners With G-III Apparel to Fuel Growth
by Zacks Equity Research
Inter Parfums (IPAR) finalizes an agreement with G-III Apparel to become the exclusive worldwide licensee for the Donna Karan and DKNY fragrance brands.
Zacks.com featured highlights Sanderson Farms, MEDIFAST, Skyline, Hudson Global and Expeditors International of Washington
by Zacks Equity Research
Sanderson Farms, MEDIFAST, Skyline, Hudson Global and Expeditors International of Washington have been highlighted in this Screen of the Week article.
The J.M. Smucker (SJM) Rewards Investors With Dividend Hike
by Zacks Equity Research
The J.M. Smucker (SJM) rewards shareholders by raising the quarterly dividend. The company is progressing with core priorities.
Dive Into DuPont Analysis & Pick 5 Top Stocks
by Sanghamitra Saha
Do you have more faith in DuPont analysis than simple ROE calculation? Tap Sanderson Farms (SAFM), MEDIFAST (MED), Skyline (SKY), Hudson Global (HSON) and Expeditors International of Washington (EXPD).
Chefs' Warehouse (CHEF) Soars 5.4%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Chefs' Warehouse (CHEF) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.